Moderna's Vaccine Portfolio Primed For Boost From Its COVID-19 Work

 
• By Brenda Sandburg

At its "Vaccines Day" with investors, Moderna execs tout the company's messenger RNA platform and say its portfolio of vaccine candidates has the potential to reach annual peak sales of up to $12bn.

Stone / United Kingdom - February 11 2020: Moderna medical compamy logo seen on the brochure with the viral masks, syringe and pills. Photo concept. Selective focus.
Moderna touts its messenger RNA and vaccines pipline to investors

More from COVID-19

More from Scrip